Promoting patient-centred healthcare around the world Regulation of Biosimilars Jo Harkness.

Slides:

Advertisements

Similar presentations

The Role of Government in Encouraging a High Standard of Ethics in the Healthcare Sector: Indonesia Experience Prof. Agus Purwadianto Senior Adviser to.

Advertisements

ECONOMIA DELLINNOVAZIONE LINNOVAZIONE NELLINDUSTRIA FARMACEUTICA parte I Prof. Stefano Capri Istituto di Economia Università Carlo Cattaneo-LIUC.

Overview of Risk management: A EU perspective Lincoln Tsang May 2008.

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)

EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance.

Good Clinical Practice in Research Clinical Trial Regulations

Registration in Europe Current situation and future outlook Thomas K ü rner, M.D. Nippon Boehringer Ingelheim Co., Ltd.

© Safeguarding public health Expert Group on Innovation in the Regulation of Healthcare products Adaptive Licencing workshop at the Wellcome Trust October.

The Paediatric Regulation

Prof. A. De Wever SAFETY, EFFICACY, QUALITY AND RISK/BENFIT RATIO Source : Marc Czarka.

FEDERAL AGENCY FOR MEDICINES AND HEALTH PRODUCTS Federal Agency for Medicines and Health Products (FAMHP) Compassionate Use and Medical Need Program Pharma.be-BeApp,

Slide 1 November 2008 Name Sarah Morgan © Crown copyright 2005 Pharmacovigilance Working Party - Role and future perspective Sarah Morgan Medicines and.

Biopharmaceutical Regulatory Requirements 1. Marketing Authorization for Chemical Entities MoH Federal Commission for the Protection against Health Risks.

Physician Perspectives on Subsequent Entry Biologics (SEBs) Michael S. Reilly, Esq. Executive Director, Alliance for Safe Biologic Medicines March 31,

S ocial scientists are interested in how different innovative medical technologies including human tissue engineered products (HTEPs) fit into the changing.

1. Within a few years, more than half of newly approved medicines will be biopharmaceuticals. To ensure safety and efficacy, the FDA created a daunting.

Role of Independent Regulatory Body for Safe Operation of NPPs Zia Hussain Shah Director, Centre for Nuclear Safety Pakistan Nuclear Regulatory Authority.

Biopharmaceutical Regulatory Requirements 40. Marketing Authorization for New Chemical Entities Health Canada’s (HC) Therapeutic Products Directorate.

The role of biosimilars in BMT Dr Bronwen Shaw Chief Medical Officer, Anthony Nolan Consultant in haematopoietic cell transplantation, Royal Marsden.

Comparison of US/EU Biosimilar Guidelines

Scope of Practice and Licensure

Revision of the Medical Device Directives The case of ‘Borderline’ Products used in a self-care context 48th AESGP Annual Meeting Nice, 6-8 June 2012 Laurent.

Biosimilars – So where are we in the EU? Robert Williams, Partner, Bird & Bird LLP (London)

EN Regional Policy EUROPEAN COMMISSION Innovation and the Structural Funds, Antwerp, 16 January 2007 Veronica Gaffey Innovative Actions Unit.

Reporting Guidelines (FP5) Karen Fabbri Scientific Officer Natural & Technological Hazards DG Research European Commission Brussels

Authorisation of medicinal products: selected challenges Rocío Salvador Roldán Pharmaceuticals Unit/DG SANCO This presentation only reflects the views.

PhAMA Position on Biosimilar Medicines Ms. Leah Goodman.

Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:

Marcel H.N. Hoefnagel 2 November 2007 BIOSIMILARS are not Generics But similar.

ABHI Presentation to RCS October MD Regulatory Reform AGENDA EU Council Conclusions June 2011 What Needs Improving Industry Recommendation for New.

Healthcare Improvement Scotland is supporting clinical engagement with NHS board Area Drug and Therapeutics Committees (ADTCs) to develop collaborative.

Biosimilars Where Are We Now? Where Are We Going? Sheldon Bradshaw January 24, 2008.

ERM and the Pharmaceutical Industry. Risk  An innate part of every aspect of life, and the business environment is of no exception  Severity, both in.

Transatlantic Administrative Simplification Workshop European Preparatory Roundtable Suzette Kox EGA Senior Director Scientific Affairs.

Copyright 2010, Morgan, Lewis & Bockius LLP Healthcare Reform--New Path for Biosimilars Kathleen M. Sanzo, Esq. Washington, DC May.

WHAT IS A BIOSIMILAR? Philip D. Home, DM, DPhil Professor of Diabetes Medicine Newcastle University Consultant Diabetologist Newcastle Diabetes Centre.

European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Periodic Safety Update Reports (PSURs)

Structural Change in Pharmaceuticals: The Growth of Biologics and Emergence of Biosimilars Henry Grabowski Duke University Conference on Structural Change,

China EU Pharmaceutical Forum

Date Insert on Master Slide Slide 1 Regulatory Framework within which patients can have safe and more convenient access to medicines Royal College of Physicians.

1 From Regulatory Intelligence to Compliance Debbie Henderson Head, Global Regulatory Policy EU Ring May 13, 2014.

SAFETY CONCERNS OF BIOSIMILARS IN TURKEY Serra Vildan Akgül¹, Sevcan Gül Akgün¹, Gülden Z. Omurtag¹, Semra Şardaş¹ ¹ Department of Pharmaceutical Toxicology,

Clinical Trials.

ICORD 2006 Kerstin Westermark Md, PhD, Assoc. prof. COMP Chairperson.

Efficacy and Safety of Medicines

MEP Interest Group on Brain, Mind and Pain

Periodic Safety Update Reports (PSUR)

Lithuania: Biotechnology

Information on Medicinal Products

Presented by Insert Name

DIA Clinical Safety and Pharmacovigilance Community

Presentation Title Your company information.

Presentation Title Your company information.

5 Tips to make your presentation more effective:

Introduction to Biosimilars

Biosimilar monoclonal antibodies Biologics are critical components in the treatment of patients with cancer. Biosimilars - biologics that are highly similar.

Structural Change in Pharmaceuticals: The Growth of Biologics and Emergence of Biosimilars Henry Grabowski Duke University Conference on Structural Change,

Helen Lee, European Commission

Understanding Biologics

Innovative Medicines Initiative:

Biosimilars in Hematologic Oncology

UKMi Observatory Observatory of recent safe medication practice research, reports, and publications Presented by Job title address.

Commission strategy to

WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:

Regulatory Cooperation in TTIP

Access to European microdata for scientific purposes

Process mapping of registration to reimbursement for new pharmaceuticals in UK Description: A systematic methodology was developed in order to create the.

Presentation transcript:

Promoting patient-centred healthcare around the world Regulation of Biosimilars Jo Harkness

Promoting patient-centred healthcare around the world Regulatory Status In 2004 two directives were introduced by the European commission These provided a regulatory framework in the EU There is a clearly defined regulatory framework in the EU

Promoting patient-centred healthcare around the world Approval process The company must provide a comprehensive file of tests undertaken In the laboratory In patients Must demonstrate that the biosimilar is safe, effective and comparable to the original innovator drug (reference product)

Promoting patient-centred healthcare around the world Additional tests required Determined by the history of the drug More complex biosimilars will require more additional testing Drugs with long history and therefore experience (e.g. insulin) will require fewer additional tests than newer drugs

Promoting patient-centred healthcare around the world Slide Title Framework for case-by-case approach to assessing biosimilars, taking into account current scientific knowledge Centralised Procedure mandatory for biopharmaceutical and biosimilars More emphasis on manufacturing processes than for generics More emphasis on pharmacovigilance than for generics

Promoting patient-centred healthcare around the world Guidelines to date: Somatotropins Recombinant erythropoietins Recombinant human Insulin Recombinant granulocyte-Colony Stimulating Factor Recombinant α-Interferons Guideline on Immunogenicity Assessment Please see EMEA website for details (reference numbers on your handouts)